FY2025 EPS Estimates for Genmab A/S Lowered by William Blair

Genmab A/S (NASDAQ:GMAB) – Investment analysts at William Blair dropped their FY2025 earnings per share estimates for shares of Genmab A/S in a research note issued to investors on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the company will post earnings of $1.38 per share for the year, down from their previous forecast of $1.60. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share.

Several other research firms also recently weighed in on GMAB. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday. Redburn Atlantic initiated coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. BMO Capital Markets restated an “outperform” rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

Shares of GMAB opened at $21.13 on Thursday. Genmab A/S has a 1-year low of $19.85 and a 1-year high of $31.88. The stock has a market cap of $13.98 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. The firm has a 50 day simple moving average of $21.07 and a 200-day simple moving average of $23.96.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter last year, the business posted $0.47 earnings per share.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently modified their holdings of GMAB. Two Sigma Advisers LP raised its stake in Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares during the last quarter. FMR LLC boosted its holdings in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after acquiring an additional 33,076 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in Genmab A/S by 6.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after acquiring an additional 14,165 shares during the last quarter. Finally, Natixis Advisors LLC grew its position in Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after acquiring an additional 47,437 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.